Sabby Management, LLC Curis Inc Transaction History

Sabby Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.47 - $17.22 $128,833 - $4.72 Million	-274,114 Reduced 54.82%	225,886 $124,000
Q3 2022 Nov 14, 2022	BUY	$0.74 - $15.01 $7,400 - $150,100	10,000 Added 2.04%	500,000 $350,000
Q2 2022 Aug 15, 2022	BUY	$0.71 - $2.43 $102,307 - $350,150	144,095 Added 41.66%	490,000 $482,000
Q1 2022 May 16, 2022	BUY	$2.31 - $5.13 $275,767 - $612,419	119,380 Added 52.7%	345,905 $823,000
Q4 2021 Feb 14, 2022	BUY	$4.45 - $8.09 $562,146 - $1.02 Million	126,325 Added 126.07%	226,525 $1.08 Million
Q3 2021 Nov 15, 2021	BUY	$6.94 - $8.85 $695,388 - $886,770	100,200 New	100,200 $785,000
Q4 2020 Feb 16, 2021	SELL	$1.08 - $8.2 $1.27 Million - $9.67 Million	-1,179,600 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$0.95 - $1.42 $1.03 Million - $1.54 Million	-1,087,468 Reduced 47.97%	1,179,600 $1.38 Million
Q2 2020 Aug 14, 2020	BUY	$0.63 - $1.7 $1.43 Million - $3.85 Million	2,267,068 New	2,267,068 $2.74 Million

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $393M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Sabby Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sabby Management, LLC with notifications on news.